• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

三阴性乳腺癌的治疗反应预测脑转移:基于评分的模型。

Treatment response as predictor for brain metastasis in triple negative breast cancer: A score-based model.

机构信息

Department of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri.

Department of Radiation Oncology, University of North Carolina, Chapel Hill, North Carolina.

出版信息

Breast J. 2019 May;25(3):363-372. doi: 10.1111/tbj.13230. Epub 2019 Mar 28.

DOI:10.1111/tbj.13230
PMID:30920124
Abstract

BACKGROUND

Triple negative breast cancer (TNBC) has worse prognosis than other subtypes of breast cancer, and many patients develop brain metastasis (BM). We developed a simple predictive model to stratify the risk of BM in TNBC patients receiving neo-adjuvant chemotherapy (NAC), surgery, and radiation therapy (RT).

METHODS

Patients with TNBC who received NAC, surgery, and RT were included. Cox proportional hazards method was used to evaluate factors associated with BM. Significant factors predictive for BM on multivariate analysis (MVA) were used to develop a risk score. Patients were divided into three risk groups: low, intermediate, and high. A receiver operating characteristic (ROC) curve was drawn to evaluate the value of the risk group in predicting BM. This predictive model was externally validated.

RESULTS

A total of 160 patients were included. The median follow-up was 47.4 months. The median age at diagnosis was 49.9 years. The 2-year freedom from BM was 90.5%. Persistent lymph node positivity, HR 8.75 (1.76-43.52, P = 0.01), and lack of downstaging, HR 3.46 (1.03-11.62, P = 0.04), were significant predictors for BM. The 2-year rate of BM was 0%, 10.7%, and 30.3% (P < 0.001) in patients belonging to low-, intermediate-, and high-risk groups, respectively. Area under the ROC curve was 0.81 (P < 0.001). This model was externally validated (C-index = 0.79).

CONCLUSIONS

Lack of downstaging and persistent lymph node positivity after NAC are associated with development of BM in TNBC. This model can be used by the clinicians to stratify patients into the three risk groups to identify those at increased risk of developing BM and potentially impact surveillance strategies.

摘要

背景

三阴性乳腺癌(TNBC)的预后比其他乳腺癌亚型差,许多患者会发生脑转移(BM)。我们开发了一种简单的预测模型,以对接受新辅助化疗(NAC)、手术和放射治疗(RT)的 TNBC 患者的 BM 风险进行分层。

方法

纳入接受 NAC、手术和 RT 的 TNBC 患者。采用 Cox 比例风险方法评估与 BM 相关的因素。多变量分析(MVA)中对 BM 有预测意义的显著因素用于建立风险评分。患者被分为低、中、高三个风险组。绘制受试者工作特征(ROC)曲线以评估风险组预测 BM 的价值。该预测模型经过外部验证。

结果

共纳入 160 例患者。中位随访时间为 47.4 个月。中位诊断年龄为 49.9 岁。2 年无 BM 生存率为 90.5%。持续性淋巴结阳性,HR 8.75(1.76-43.52,P=0.01)和降期不足,HR 3.46(1.03-11.62,P=0.04)是 BM 的显著预测因素。低、中、高危组患者 2 年 BM 发生率分别为 0%、10.7%和 30.3%(P<0.001)。ROC 曲线下面积为 0.81(P<0.001)。该模型经过外部验证(C 指数=0.79)。

结论

NAC 后降期不足和持续性淋巴结阳性与 TNBC 患者 BM 的发生相关。该模型可用于临床医生将患者分为三个风险组,以识别那些发生 BM 风险增加的患者,并可能影响监测策略。

相似文献

1
Treatment response as predictor for brain metastasis in triple negative breast cancer: A score-based model.三阴性乳腺癌的治疗反应预测脑转移:基于评分的模型。
Breast J. 2019 May;25(3):363-372. doi: 10.1111/tbj.13230. Epub 2019 Mar 28.
2
Impact of neoadjuvant chemotherapy on axillary nodal involvement in patients with clinically node negative triple negative breast cancer.新辅助化疗对临床腋窝淋巴结阴性的三阴性乳腺癌患者腋窝淋巴结受累情况的影响。
J Surg Oncol. 2015 Feb;111(2):198-202. doi: 10.1002/jso.23790. Epub 2014 Sep 29.
3
Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy.除腋窝淋巴结转移外,体重指数和绝经状态是新辅助化疗治疗三阴性乳腺癌的预后决定因素。
PLoS One. 2015 Dec 18;10(12):e0144359. doi: 10.1371/journal.pone.0144359. eCollection 2015.
4
[Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer. Its relation with molecular subtypes].[新辅助化疗后乳腺癌前哨淋巴结活检及其与分子亚型的关系]
Rev Esp Med Nucl Imagen Mol. 2014 Nov-Dec;33(6):340-5. doi: 10.1016/j.remn.2014.04.003. Epub 2014 May 21.
5
A Nomogram to Predict the Pathologic Complete Response of Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer Based on Simple Laboratory Indicators.基于简单实验室指标的三阴性乳腺癌新辅助化疗病理完全缓解预测列线图。
Ann Surg Oncol. 2019 Nov;26(12):3912-3919. doi: 10.1245/s10434-019-07655-7. Epub 2019 Jul 29.
6
Survival impact and predictive factors of axillary recurrence after sentinel biopsy.前哨淋巴结活检后腋窝复发的生存影响及预测因素
Eur J Cancer. 2016 May;58:73-82. doi: 10.1016/j.ejca.2016.01.019. Epub 2016 Mar 11.
7
Predicting Non-sentinel Lymph Node Metastases in Patients with a Positive Sentinel Lymph Node After Neoadjuvant Chemotherapy.预测新辅助化疗后前哨淋巴结阳性患者的非前哨淋巴结转移。
Ann Surg Oncol. 2018 Oct;25(10):2867-2874. doi: 10.1245/s10434-018-6578-3. Epub 2018 Jun 28.
8
Lymph Node Ratio Analysis After Neoadjuvant Chemotherapy is Prognostic in Hormone Receptor-Positive and Triple-Negative Breast Cancer.新辅助化疗后淋巴结比率分析对激素受体阳性和三阴性乳腺癌具有预后价值。
Ann Surg Oncol. 2016 Oct;23(10):3310-6. doi: 10.1245/s10434-016-5319-8. Epub 2016 Jul 11.
9
Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study.新辅助化疗后前哨淋巴结活检而不进行腋窝淋巴结清扫对选定患者准确且安全:GANEA 2 研究。
Breast Cancer Res Treat. 2019 Jan;173(2):343-352. doi: 10.1007/s10549-018-5004-7. Epub 2018 Oct 20.
10
Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With an Initial Diagnosis of Cytology-Proven Lymph Node-Positive Breast Cancer.初诊为经细胞学证实淋巴结阳性乳腺癌患者新辅助化疗后的前哨淋巴结活检
Clin Breast Cancer. 2016 Aug;16(4):299-304. doi: 10.1016/j.clbc.2016.02.009. Epub 2016 Feb 11.

引用本文的文献

1
Repurposing chlorpromazine for the treatment of triple-negative breast cancer growth and metastasis based on modulation of mitochondria-mediated apoptosis and autophagy/mitophagy.基于对线粒体介导的细胞凋亡及自噬/线粒体自噬的调控,重新利用氯丙嗪治疗三阴性乳腺癌的生长和转移。
Br J Cancer. 2025 Apr 11. doi: 10.1038/s41416-025-02992-9.
2
Development and external validation of a prediction model for brain metastases in patients with metastatic breast cancer.开发和外部验证转移性乳腺癌患者脑转移预测模型。
J Cancer Res Clin Oncol. 2023 Oct;149(13):12333-12353. doi: 10.1007/s00432-023-05125-y. Epub 2023 Jul 11.
3
A pre-operative MRI-based brain metastasis risk-prediction model for triple-negative breast cancer.
一种基于术前磁共振成像的三阴性乳腺癌脑转移风险预测模型。
Gland Surg. 2021 Sep;10(9):2715-2723. doi: 10.21037/gs-21-537.
4
A risk stratification model for predicting brain metastasis and brain screening benefit in patients with metastatic triple-negative breast cancer.用于预测转移性三阴性乳腺癌患者脑转移和脑筛查获益的风险分层模型。
Cancer Med. 2020 Nov;9(22):8540-8551. doi: 10.1002/cam4.3449. Epub 2020 Sep 18.
5
Evaluation of imaging findings and prognostic factors after whole-brain radiotherapy for carcinomatous meningitis from breast cancer: A retrospective analysis.乳腺癌性脑膜炎全脑放疗后影像学表现及预后因素评估:一项回顾性分析
Medicine (Baltimore). 2020 Jul 31;99(31):e21333. doi: 10.1097/MD.0000000000021333.
6
Predictors of Neoadjuvant Chemotherapy Response in Breast Cancer: A Review.乳腺癌新辅助化疗反应的预测因素:综述
Onco Targets Ther. 2020 Jun 22;13:5887-5899. doi: 10.2147/OTT.S253056. eCollection 2020.
7
Pericyte-secreted IGF2 promotes breast cancer brain metastasis formation.周细胞分泌的 IGF2 促进乳腺癌脑转移的形成。
Mol Oncol. 2020 Sep;14(9):2040-2057. doi: 10.1002/1878-0261.12752. Epub 2020 Jun 26.